Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

2.

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.

Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, Lu C, Rescigno P, Kolinsky M, Bertan C, Seed G, Riisnaes R, Miranda S, Crespo M, Pereira R, Ferreira A, Fowler G, Ebbs B, Flohr P, Neeb A, Bianchini D, Petremolo A, Sumanasuriya S, Paschalis A, Mateo J, Tunariu N, Yuan W, Carreira S, Plymate SR, Luo J, de Bono JS.

Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285-4. doi: 10.1016/j.eururo.2019.04.006. [Epub ahead of print]

3.

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, Rengel-Puertas A, Ouhlen M, Crespo M, Berghuis AMS, Andree KC, Vidotto R, Trapp EK, Tzschaschel M, Colomba E, Fowler G, Flohr P, Rescigno P, Fontes MS, Zamarchi R, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Farace F, De Bono J, IJzerman MJ, Terstappen LWMM.

Oncotarget. 2018 Nov 2;9(86):35705-35716. doi: 10.18632/oncotarget.26298. eCollection 2018 Nov 2.

4.

Immunotherapy for lethal prostate cancer.

Rescigno P, de Bono JS.

Nat Rev Urol. 2019 Feb;16(2):69-70. doi: 10.1038/s41585-018-0121-y. No abstract available.

PMID:
30467373
5.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

6.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS.

Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16.

7.

RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.

Nava Rodrigues D, Casiraghi N, Romanel A, Crespo M, Miranda S, Rescigno P, Figueiredo I, Riisnaes R, Carreira S, Sumanasuriya S, Gasperini P, Sharp A, Mateo J, Makay A, McNair C, Schiewer M, Knudsen K, Boysen G, Demichelis F, de Bono JS.

Clin Cancer Res. 2019 Jan 15;25(2):687-697. doi: 10.1158/1078-0432.CCR-18-2068. Epub 2018 Sep 26.

PMID:
30257982
8.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

9.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
10.

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira FM, Atkin M, Clarke M, Goodall J, Sharp A, MacDonald T, Rubin MA, Yuan W, Barbieri CE, Carreira S, Mateo J, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5585-5593. doi: 10.1158/1078-0432.CCR-18-0937. Epub 2018 Aug 1.

PMID:
30068710
11.

Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.

Rescigno P, Chandler R, de Bono J.

Curr Opin Support Palliat Care. 2018 Sep;12(3):339-343. doi: 10.1097/SPC.0000000000000358.

PMID:
29979319
12.

Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors.

Condello C, Rescigno P, Ottaviano M, Nappi L, Tortora M, de Placido S, Palmieri G.

Future Oncol. 2018 Jul;14(16):1591-1599. doi: 10.2217/fon-2017-0670. Epub 2018 Jun 29. Review.

PMID:
29956548
13.

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.

Rescigno P, Lorente D, Dolling D, Ferraldeschi R, Rodrigues DN, Riisnaes R, Miranda S, Bianchini D, Zafeiriou Z, Sideris S, Ferreira A, Figueiredo I, Sumanasuriya S, Mateo J, Perez-Lopez R, Sharp A, Tunariu N, de Bono JS.

Eur Urol Oncol. 2018 May;1(1):71-77. doi: 10.1016/j.euo.2018.02.006.

14.

Hypoxia and Noncoding RNAs in Taxane Resistance.

Pucci P, Rescigno P, Sumanasuriya S, de Bono J, Crea F.

Trends Pharmacol Sci. 2018 Aug;39(8):695-709. doi: 10.1016/j.tips.2018.05.002. Epub 2018 Jun 8. Review.

PMID:
29891252
15.

Long term deficiency of vitamin D in germ cell testicular cancer survivors.

Nappi L, Ottaviano M, Rescigno P, Fazli L, Gleave ME, Damiano V, De Placido S, Palmieri G.

Oncotarget. 2018 Apr 20;9(30):21078-21085. doi: 10.18632/oncotarget.24925. eCollection 2018 Apr 20.

16.

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.

Nanou A, Coumans FAW, van Dalum G, Zeune LL, Dolling D, Onstenk W, Crespo M, Fontes MS, Rescigno P, Fowler G, Flohr P, Brune C, Sleijfer S, de Bono JS, Terstappen LWMM.

Oncotarget. 2018 Apr 10;9(27):19283-19293. doi: 10.18632/oncotarget.25019. eCollection 2018 Apr 10.

17.

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.

Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.

18.

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.

Cato L, Neeb A, Sharp A, Buzón V, Ficarro SB, Yang L, Muhle-Goll C, Kuznik NC, Riisnaes R, Nava Rodrigues D, Armant O, Gourain V, Adelmant G, Ntim EA, Westerling T, Dolling D, Rescigno P, Figueiredo I, Fauser F, Wu J, Rottenberg JT, Shatkina L, Ester C, Luy B, Puchta H, Troppmair J, Jung N, Bräse S, Strähle U, Marto JA, Nienhaus GU, Al-Lazikani B, Salvatella X, de Bono JS, Cato AC, Brown M.

Elife. 2017 Aug 10;6. pii: e27159. doi: 10.7554/eLife.27159.

19.

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.

Lorente D, Ravi P, Mehra N, Pezaro C, Omlin A, Gilman A, Miranda M, Rescigno P, Kolinsky M, Porta N, Bianchini D, Tunariu N, Perez R, Mateo J, Payne H, Terstappen L, IJzerman M, Hall E, de Bono J.

Eur Urol Focus. 2018 Mar;4(2):235-244. doi: 10.1016/j.euf.2016.09.005. Epub 2016 Oct 10.

20.

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.

Bianchini D, Lorente D, Rescigno P, Zafeiriou Z, Psychopaida E, O'Sullivan H, Alaras M, Kolinsky M, Sumanasuriya S, Sousa Fontes M, Mateo J, Perez Lopez R, Tunariu N, Fotiadis N, Kumar P, Tree A, Van As N, Khoo V, Parker C, Eeles R, Thompson A, Dearnaley D, de Bono JS.

Clin Genitourin Cancer. 2017 Oct;15(5):e801-e807. doi: 10.1016/j.clgc.2017.04.013. Epub 2017 Apr 26.

21.

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators.

Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.

22.

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.

Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, Wang C, Zhang LZ, Wang Y, Gil V, Aziz S, Christova R, Rodrigues DN, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu DY, de Bono J, Wu H.

Ann Oncol. 2017 Jul 1;28(7):1495-1507. doi: 10.1093/annonc/mdx165.

23.

Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.

Rescigno P, Rodrigues DN, de Bono JS.

BJU Int. 2017 Jan;119(1):3-4. doi: 10.1111/bju.13550. No abstract available.

24.

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N.

Radiology. 2017 Apr;283(1):168-177. doi: 10.1148/radiol.2016160646. Epub 2016 Nov 22.

26.

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.

Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.

27.

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.

Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS.

Eur Urol. 2016 Nov;70(5):724-731. doi: 10.1016/j.eururo.2016.02.055. Epub 2016 Mar 7.

28.

Chemical or Surgical Castration--Is This Still an Important Question?

Kolinsky M, Rescigno P, de Bono JS.

JAMA Oncol. 2016 Apr;2(4):437-8. doi: 10.1001/jamaoncol.2015.4918. No abstract available.

PMID:
26719908
29.

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, Carreira S, Goodall J, Wingate A, Ferraldeschi R, Tunariu N, Flohr P, De Giorgi U, de Bono JS, Demichelis F, Attard G.

Sci Transl Med. 2015 Nov 4;7(312):312re10. doi: 10.1126/scitranslmed.aac9511.

30.

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J.

Eur Urol. 2015 Apr;67(4):795-802. doi: 10.1016/j.eururo.2014.10.027. Epub 2014 Nov 4.

31.

Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.

De Placido S, Rescigno P, Federico P, Buonerba C, Bosso D, Puglia L, Izzo M, Policastro T, Di Lorenzo G.

World J Clin Cases. 2014 Jun 16;2(6):228-31. doi: 10.12998/wjcc.v2.i6.228.

32.

The potential detrimental effect of corticosteroids in prostate cancer.

Rescigno P, di Lorenzo G.

Future Oncol. 2014 Feb;10(3):325-7. doi: 10.2217/fon.13.270. No abstract available.

33.

Long lasting response to second-line everolimus in kidney cancer.

Virtuoso A, Policastro T, Izzo M, Federico P, Buonerba C, Rescigno P, Di Lorenzo G.

World J Clin Cases. 2013 Aug 16;1(5):166-8. doi: 10.12998/wjcc.v1.i5.166.

34.

New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.

Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M.

Biomed Res Int. 2013;2013:852839. doi: 10.1155/2013/852839. Epub 2013 Aug 25. Review.

35.

Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.

Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudioso G, Terracciano D, Di Trolio R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA, Franco R.

J Transl Med. 2013 Jul 2;11:161. doi: 10.1186/1479-5876-11-161.

36.

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G.

Future Oncol. 2013 Jun;9(6):889-97. doi: 10.2217/fon.13.39.

PMID:
23718309
37.

Non-AIDS-related Kaposi's sarcoma: A single-institution experience.

Rescigno P, Di Trolio R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G.

World J Clin Oncol. 2013 May 10;4(2):52-7. doi: 10.5306/wjco.v4.i2.52.

38.

Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor.

Moretto R, Cella CA, Raimondo L, Formisano L, Nappi L, Rescigno P, Buonerba C, Calabrese F, Ottaviano M, Di Lorenzo G, Matano E, Damiano V, Palmieri G.

Anticancer Drugs. 2013 Aug;24(7):759-64. doi: 10.1097/CAD.0b013e328362a68b.

PMID:
23695010
39.

The economic crisis and cancer chemotherapy: the role of the oncologist.

Rescigno P, Imbevaro S, Jirillo A.

Tumori. 2012 Jul-Aug;98(4):532-3. doi: 10.1700/1146.12650. No abstract available.

PMID:
23052172
40.

Peg-filgrastim and cabazitaxel in prostate cancer patients.

Di Lorenzo G, DʼAniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S.

Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc.

PMID:
23044721
41.

New perspectives in the therapy of castration resistant prostate cancer.

Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G.

Curr Drug Targets. 2012 Dec;13(13):1676-86. Review.

PMID:
23043326
42.

Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.

Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S.

BJU Int. 2012 Dec;110(11 Pt B):E661-6. doi: 10.1111/j.1464-410X.2012.11453.x. Epub 2012 Sep 10.

43.

Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.

Rescigno P, Matano E, Raimondo L, Mainolfi C, Federico P, Buonerba C, Di Trolio R, D'Aniello C, Damiano V, Palmieri G, De Placido S, Di Lorenzo G.

Anticancer Drugs. 2012 Jun;23(5):573-7. doi: 10.1097/CAD.0b013e328350ead7.

PMID:
22481064
44.

Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.

Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V.

Eur Urol. 2011 Dec;60(6):1280-4. doi: 10.1016/j.eururo.2011.08.028. Epub 2011 Aug 22.

PMID:
21871710
45.

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.

Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Erratum in: Cancer Chemother Pharmacol. 2011 Jun;67(6):1463.

PMID:
21365219
46.

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.

Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24.

PMID:
20884115
47.

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G.

BJU Int. 2011 Jan;107(2):234-9. doi: 10.1111/j.1464-410X.2010.09498.x.

48.

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S.

J Clin Oncol. 2009 Sep 20;27(27):4469-74. doi: 10.1200/JCO.2009.22.6480. Epub 2009 Aug 3.

PMID:
19652053
49.

Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.

Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S.

Anticancer Drugs. 2009 Apr;20(4):277-80. doi: 10.1097/CAD.0b013e328329a293.

PMID:
19262371

Supplemental Content

Loading ...
Support Center